Cytokinetics Announces Presentation of Phase IIA Clinical Trial Data of Tirasemtiv in Patients with Myasthenia Gravis

[at noodls] – Positive Results from Evidence of Effect Trial Inform Translation of Novel Mechanism of Action South San Francisco, CA – March 21, 2013 Cytokinetics, Incorporated (Nasdaq: CYTK) announced the presentation … more

View todays social media effects on CYTK

View the latest stocks trending across Twitter. Click to view dashboard

See who Cytokinetics is hiring next, click here to view